Nivobotulinumtoxina

Summary

Nivobotulinumtoxina (CHEMBL3990013) is a phase-3 clinical-stage protein.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3990013
Name	Nivobotulinumtoxina
Type	Protein
Max phase	3

Also known as: MT 10109, MT-10109, MT10109, MT10109L, Nivobotulinumtoxina, NIVOBOTULINUMTOXINA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	4
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03721016	PHASE3	COMPLETED	MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
NCT03732833	PHASE3	COMPLETED	MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
NCT03785145	PHASE3	COMPLETED	MT10109L in the Treatment of Lateral Canthal Lines
NCT03795922	PHASE3	COMPLETED	MT10109L in the Treatment of Glabellar Lines
NCT01485601	PHASE2	COMPLETED	Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines
NCT01588574	PHASE2	COMPLETED	Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).